[203/212Pb]Pb-VMT-α-NET as a novel theranostic agent for targeted alpha radiotherapy—first clinical experience
Imaging with [<sup>203</sup>Pb]Pb-VMT-α-NET followed by a single dose of [<sup>212</sup>Pb]Pb-VMT-α-NET appears to be well tolerated with promising efficacy, even in a heterogenous and heavily pretreated patient population. Further studies are warranted to examine tolerability and efficacy over multiple treatment cycles in larger patient populations.
Authors
- David Kästner (ORCID: https://orcid.org/0009-0003-6004-8639)
- Ralph A. Bundschuh (ORCID: https://orcid.org/0000-0001-7291-9372)
- Michael K. Schultz (ORCID: https://orcid.org/0000-0002-4554-2212)
- Claudia Brogsitter
- Enrico Michler (ORCID: https://orcid.org/0000-0002-4404-0114)
- Marc Pretze (ORCID: https://orcid.org/0000-0002-6432-5694)
- Robert Freudenberg (ORCID: https://orcid.org/0000-0002-1970-6957)
- Holger Hartmann
- Jörg Kotzerke
Institutions
- Io Therapeutics (United States) (US)
- University Hospital Carl Gustav Carus (DE)
- Technische Universität Dresden (DE)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1007/s00259-025-07269-0
- Citations
- 8
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 10.83